Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies.

The production of the oncometabolite 2-hydroxyglutarate (2-HG) has been associated with c-MYC overexpression. c-MYC also regulates glutamine metabolism and drives progression of asymptomatic precursor plasma cell (PC) malignancies to symptomatic multiple myeloma (MM). However, the presence of 2-HG and its clinical significance in PC malignancies is unknown. By performing 13C stable isotope resolved metabolomics (SIRM) using U[13C6]Glucose and U[13C5]Glutamine in human myeloma cell lines (HMCLs), we show that 2-HG is produced in clonal PCs and is derived predominantly from glutamine anaplerosis into the TCA cycle. Furthermore, the 13C SIRM studies in HMCLs also demonstrate that glutamine is preferentially utilized by the TCA cycle compared with glucose. Finally, measuring the levels of 2-HG in the BM supernatant and peripheral blood plasma from patients with precursor PC malignancies such as smoldering MM (SMM) demonstrates that relatively elevated levels of 2-HG are associated with higher levels of c-MYC expression in the BM clonal PCs and with a subsequent shorter time to progression (TTP) to MM. Thus, measuring 2-HG levels in BM supernatant or peripheral blood plasma of SMM patients offers potential early identification of those patients at high risk of progression to MM, who could benefit from early therapeutic intervention.

[1]  C. Corbet,et al.  Cancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fueling. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[2]  C. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[3]  Frédérick A. Mallette,et al.  The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway , 2016, Nature Communications.

[4]  C. Mancini,et al.  Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. , 2016, Blood.

[5]  A. Krämer,et al.  Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia , 2016, Leukemia.

[6]  N. Pavlova,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[7]  S. Venneti,et al.  2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS , 2015, Brain pathology.

[8]  J. W. Allwood,et al.  Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma , 2015, Blood Cancer Journal.

[9]  H. Dombret,et al.  Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Sarah J. Kurley,et al.  MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.

[11]  P. L. Bergsagel,et al.  Smoldering multiple myeloma requiring treatment: time for a new definition? , 2013, Blood.

[12]  F. Prósper,et al.  Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission , 2013, Clinical Cancer Research.

[13]  G. Morgan,et al.  Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease , 2013, PloS one.

[14]  A. Iafrate,et al.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.

[15]  K. Sharp,et al.  Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production , 2012, Oncogene.

[16]  C. Dang Links between metabolism and cancer. , 2012, Genes & development.

[17]  A. Lane,et al.  Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.

[18]  G. Mulligan,et al.  Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma , 2011, Leukemia.

[19]  C. Dang,et al.  Therapeutic targeting of cancer cell metabolism , 2011, Journal of Molecular Medicine.

[20]  C. Dang Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. , 2010, Cancer research.

[21]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[22]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[23]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[24]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[25]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[26]  D. Matthews,et al.  Determination of complex isotopomer patterns in isotopically labeled compounds by mass spectrometry. , 2005, Analytical chemistry.

[27]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[28]  Michael Hummel,et al.  Supplementary Figure 3 , 2010 .

[29]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[30]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.